

D.3	Chlorpromazine and haloperidol – psychotic disorders – EMLc
Draft recommendation	<input checked="" type="checkbox"/> Recommended <input type="checkbox"/> Not recommended Justification: Based on lack of efficacy and safety concerns, deletion of Chlorpromazine and haloperidol for treatment of psychotic disorders of children from EMLc is recommended. The WHO mhGAP guideline do not recognize the use of antipsychotics as a viable option for the treatment of any mental health condition in children.
Does the proposed medicine address a relevant public health need?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> Not applicable Comments:
Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process)	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> Not applicable Comments:
Does adequate evidence exist for the safety/harms associated with the proposed medicine? (this may be evidence included in the application, and/or additional evidence identified during the review process)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable Comments:
Are there any adverse effects of concern, or that may require special monitoring?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable Comments:

24th WHO Expert Committee on Selection and Use of Essential Medicines
Expert review

<p>Are there any special requirements for the safe, effective and appropriate use of the medicines?</p> <p>(e.g. laboratory diagnostic and/or monitoring tests, specialized training for health providers, etc)</p>	<p><input checked="" type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments: May require specialized health care provider.</p>
<p>Are there any issues regarding cost, cost-effectiveness, affordability and/or access for the medicine in different settings?</p>	<p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p><input checked="" type="checkbox"/> Not applicable</p> <p>Comments:</p>
<p>Are there any issues regarding the registration of the medicine by national regulatory authorities?</p> <p>(e.g. accelerated approval, lack of regulatory approval, off-label indication)</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments:</p>
<p>Is the proposed medicine recommended for use in a current WHO guideline?</p> <p>(refer to: https://www.who.int/publications/who-guidelines)</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments: The WHO mhGAP guideline does not recognize the use of antipsychotics as a viable option for the treatment of any mental health condition in children.</p>